The Influence of Antidiabetic Medications on Diagnostic Accuracy of Plasma Tau 217 Assay

References

1. AshtonN.J. BrumW.S. Di MolfettaG. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology.JAMA Neurol.202481325526310.1001/jamaneurol.2023.531938252443
   [Google Scholar]
2. ZhangS. ZhongJ. XuL. Truncated Dyrk1A aggravates neuronal apoptosis by inhibiting ASF‐mediated Bcl‐x exon 2b inclusion.CNS Neurosci. Ther.2024304e1449337864462
   [Google Scholar]
3. LeeH. HoeH.S. Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling.Pharmacol. Res.202319010672510.1016/j.phrs.2023.10672536907286
   [Google Scholar]
4. DelabarJ.M. GomesM.A.G.B. FructuosoM. EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model.Eur. J. Med. Chem.202426511609810.1016/j.ejmech.2023.11609838171148
   [Google Scholar]
5. MoranC. LacyM.E. WhitmerR.A. Glycemic control over multiple decades and dementia risk in people with type 2 diabetes.JAMA Neurol.202380659760410.1001/jamaneurol.2023.069737067815
   [Google Scholar]
6. SadybekovA.V. KatritchV. Computational approaches streamlining drug discovery.Nature2023616795867368510.1038/s41586‑023‑05905‑z37100941
   [Google Scholar]